National Heart, Lung and Blood Institute. Risk Assessment Tool for Estimating Your 10-year Risk of Having a Heart Attack. http://cvdrisk.nhlbi.nih.gov. Accessed 27 Sept 2015.
Framingham Heart Study. Stroke risk calculator. Based on D’Agostino et al. Stroke Risk Profile: Adjustment for Antihypertensive Medication. Stroke. 1994;25:40–3.
Article
Google Scholar
National Cancer Institute. Colorectal Cancer Risk Assessment Tool. http://www.cancer.gov/colorectalcancerrisk/. Accessed 27 Sept 2015.
Mendis S, Puska P, Norrving B. WHO | Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2011. http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/. Accessed 27 Sept 2015.
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012;33:1635–701.
Article
CAS
PubMed
Google Scholar
United States Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2009;150:396–404.
Article
Google Scholar
United States Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;146:361–4.
Article
Google Scholar
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.
Article
PubMed
PubMed Central
Google Scholar
Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ. 2008;336:1049–51.
Article
PubMed
PubMed Central
Google Scholar
Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e637S–68.
Article
CAS
PubMed
PubMed Central
Google Scholar
JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100 Suppl:ii1–ii67.
Google Scholar
Yu T, Vollenweider D, Varadhan R, Li T, Boyd C, Puhan MA. Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines. BMC Med. 2013;11:7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Habbema JDF, Wilt TJ, Etzioni R, Nelson HD, Schechter CB, Lawrence WF, et al. Models in the development of clinical practice guidelines. Ann Intern Med. 2014;161:812.
Article
PubMed
Google Scholar
Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162:115–24. e2.
Article
CAS
PubMed
Google Scholar
Man-Son-Hing M, Laupacis A, O’Connor AM, Coyle D, Berquist R, McAlister F. Patient preference-based treatment thresholds and recommendations: a comparison of decision-analytic modeling with the probability-tradeoff technique. Med Decis Making. 2000;20:394–403.
Article
CAS
PubMed
Google Scholar
Fried TR, Tinetti ME, Towle V, O’Leary JR, Iannone L. Effects of benefits and harms on older persons’ willingness to take medication for primary cardiovascular prevention. Arch Intern Med. 2011;171:923–8.
PubMed
PubMed Central
Google Scholar
Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen. J Natl Cancer Inst. 1999;91:1829–46.
Article
CAS
PubMed
Google Scholar
Greenhalgh T, Howick J, Maskrey N. Evidence based medicine: a movement in crisis? BMJ. 2014;348:g3725.
Article
PubMed
PubMed Central
Google Scholar
Graham ID, Tetroe J. Some theoretical underpinnings of knowledge translation. Acad Emerg Med. 2007;14:936–41.
Article
PubMed
Google Scholar
Pronovost PJ. Enhancing physicians’ use of clinical guidelines. JAMA. 2013;310:2501–2.
Article
CAS
PubMed
Google Scholar
Aspirin for the Prevention of Cardiovascular Disease: Preventive Medication. http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=aspirin. Accessed 27 Sept 2015.
Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9:259–67.
Article
CAS
PubMed
Google Scholar
Puhan MA, Singh S, Weiss CO, Varadhan R, Boyd CM. A framework for organizing and selecting quantitative approaches for benefit-harm assessment. BMC Med Res Methodol. 2012;12:173.
Article
PubMed
PubMed Central
Google Scholar
Boyd C, Singh S, Varadhan R, Weiss CO, Sharma R, Bass EB, et al. Methods for benefit and harm assessment in systematic reviews. Agency for Healthcare Research and Quality. 2012;12:EHC150-EF.
Google Scholar
Stegeman I, Bossuyt PM, Yu T, Boyd C, Puhan MA. Aspirin for primary prevention of cardiovascular disease and cancer. A benefit and harm analysis. PLoS One. 2015;10:e0127194.
Article
PubMed
PubMed Central
Google Scholar
Puhan MA, Singh S, Weiss CO, Varadhan R, Sharma R, Boyd CM. Evaluation of the benefits and harms of aspirin for primary prevention of cardiovascular events. Agency for Healthcare Research and Quality. 2013;12:EHC149-EF.
Google Scholar
Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–13.
Article
CAS
PubMed
Google Scholar
Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–27.
Article
CAS
PubMed
Google Scholar
NHLBI Incidence and Prevalence Chartbook. https://www.nhlbi.nih.gov/research/reports/2006-incidence-chart-book.htm. Accessed 27 Sept 2015.
Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke. 2009;40:394–9.
Article
PubMed
Google Scholar
U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2012 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2014. www.cdc.gov/uscs. Accessed 27 Sept 2015.
Centers for Disease Control and Prevention. Deaths: Final Data for 2013. National Vital Statistics Reports. Volume 64, Number 2. http://www.cdc.gov/nchs/deaths.htm. Accessed 13 July 2015.
Cost Effectiveness Analysis Registry. Tufts Medical Center, USA, www.cearegistry.org. Accessed 27 Sept 2015.
Bata IR, Gregor RD, Wolf HK, Brownell B. Trends in five-year survival of patients discharged after acute myocardial infarction. Can J Cardiol. 2006;22:399–404.
Article
PubMed
PubMed Central
Google Scholar
Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke. 2000;31:2080–6.
Article
CAS
PubMed
Google Scholar
Roberts SE, Button LA, Williams JG. Prognosis following upper gastrointestinal bleeding. PLoS One. 2012;7:e49507.
Article
CAS
PubMed
PubMed Central
Google Scholar
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2012. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/. Accessed 27 Sept 2015.
Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ. 2004;328:371.
Article
PubMed
PubMed Central
Google Scholar
R Foundation for Statistical Computing. R: A language and environment for statistical computing. 2014. http://www.r-project.org/. Accessed 27 Sept 2015.
Thorat MA, Cuzick J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol. 2015;30:5–18.
Article
CAS
PubMed
Google Scholar
Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22.
Article
PubMed
PubMed Central
Google Scholar
Puhan MA, Guyatt GH, Montori VM, Bhandari M, Devereaux PJ, Griffith L, et al. The standard gamble demonstrated lower reliability than the feeling thermometer. J Clin Epidemiol. 2005;58:458–65.
Article
PubMed
Google Scholar
Brett Hauber A, Fairchild AO, Reed JF. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature. Appl Health Econ Health Policy. 2013;11:319–29.
Article
CAS
PubMed
Google Scholar
Flynn TN. Valuing citizen and patient preferences in health: recent developments in three types of best-worst scaling. Expert Rev Pharmacoecon Outcomes Res. 2010;10:259–67.
Article
PubMed
Google Scholar
Büchi S, Sensky T, Sharpe L, Timberlake N. Graphic representation of illness: a novel method of measuring patients’ perceptions of the impact of illness. Psychother Psychosom. 1998;67:222–5.
Article
PubMed
Google Scholar
Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, et al. Evidence-based risk communication: a systematic review. Ann Intern Med. 2014;161:270–80.
Article
PubMed
Google Scholar
Stacey D, Légaré F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431.
PubMed
Google Scholar
Ademi Z, Liew D, Hollingsworth B, Steg PG, Bhatt DL, Reid CM. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort. Cardiovasc Ther. 2013;31:45–52.
Article
PubMed
Google Scholar
Clinical Trials Gov. https://clinicaltrials.gov/ct2/search. Accessed 27 Sept 2015.
Yu T, Fain K, Boyd CM, Singh S, Weiss CO, Li T, et al. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014;69:616–22.
Article
PubMed
Google Scholar
Mt-Isa S, Hallgreen CE, Wang N, Callréus T, Genov G, Hirsch I, et al. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf. 2014;23:667–78.
Article
PubMed
Google Scholar
Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015;26:47–57.
Article
CAS
PubMed
Google Scholar